证券研究报告 2025 年 08 月 24 日 湘财证券研究所 行业研究 疫苗行业周报 6 家疫苗企业发布中报，关注中报业绩表现 相关研究： 1. 《疫苗领域创新突破 国内外 进展显著》20250810 2. 《首款疫苗产品通过商保创 新药目录审查，有望开辟创新疫 苗新支付通道》20250817 行业评级：增持（维持） 近十二个月行业表现 -10 0 10 20 30 40 24/08 24/11 25/02 25/05 沪深300_累计 疫苗_累计 | % | 1 个月 | 3 个月 | 12 个月 | | --- | --- | --- | --- | | 相对收益 | -1 | 3 | -12 | | 绝对收益 | 5 | 17 | 20 | 注：相对收益与沪深 300 相比 分析师：许雯 证书编号：S0500517110001 Tel：021-50293534 Email：xw3315@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点： 国内外疫苗动态 （1）国药集团中国生物武汉生物制品研究所研制的口服六价重配轮状病毒减 毒活疫苗（Vero 细胞）正式获得国家药品监 ...

人民财讯8月18日电，近日，智飞生物（300122）全资子公司北京智飞绿竹自主研发的吸附无细胞百白 破(组分)联合疫苗(成人及青少年用)获得国家药品监督管理局的药物临床试验申请受理通知书，标志着 智飞生物在多联疫苗研发领域取得重要突破，有望填补国内成人及青少年百白破加强免疫疫苗的市场空 白。 ...

Core Viewpoint - The announcement indicates that Zhifei Biological's subsidiary has received approval for clinical trials of a new acellular DTP vaccine for adults and adolescents, filling a gap in the market for this demographic in China [1] Group 1: Company Developments - Zhifei Biological's wholly-owned subsidiary, Beijing Zhifei Green Bamboo Biological Pharmaceutical Co., Ltd., has developed an acellular DTP (Diphtheria, Tetanus, Pertussis) combined vaccine [1] - The vaccine is intended for healthy individuals aged 7 and above to prevent whooping cough, diphtheria, and tetanus [1] - The National Medical Products Administration has accepted the drug clinical trial application, allowing clinical trials to commence if no objections are raised within 60 days [1] Group 2: Market Context - Currently, there are no approved acellular DTP vaccines available for adolescents and adults in the domestic market [1]